drugset / Trial / NCT05451940
Hydroxyurea and EPO in Sickle Cell Disease
Phase 1/2
Completed
17 enrolled
Julia Xu
American Society of Hematology · collabCarnegie Mellon University · collab
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).
Timeline
- Start
- 2023-05-25
- Primary completion
- 2024-12-13
- Completion
- 2025-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | — | Subcutaneous |
| Background | Hydroxyurea | Other / unclassified | — | Oral |